Halozyme Therapeutics Inc (HALO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Halozyme Therapeutics Inc (HALO) has a cash flow conversion efficiency ratio of 0.354x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($178.60 Million) by net assets ($503.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Halozyme Therapeutics Inc worth for the company's overall valuation and market capitalisation.
Halozyme Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Halozyme Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Halozyme Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Halozyme Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Halozyme Therapeutics Inc cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aritzia Inc
TO:ATZ
|
0.266x |
|
Broadex Technologies Co Ltd
SHE:300548
|
0.067x |
|
Restaurant Brands International Limited Partnership
TO:QSP-UN
|
0.043x |
|
Viper Energy Ut
NASDAQ:VNOM
|
0.047x |
|
Finning International Inc.
TO:FTT
|
0.021x |
|
Quinenco
SN:QUINENCO
|
0.000x |
|
Zabka Group S.A.
WAR:ZAB
|
1.097x |
|
Autoliv Inc
NYSE:ALV
|
0.174x |
Annual Cash Flow Conversion Efficiency for Halozyme Therapeutics Inc (2001–2024)
The table below shows the annual cash flow conversion efficiency of Halozyme Therapeutics Inc from 2001 to 2024. View today's stock price for Halozyme Therapeutics Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.82 Million | $479.06 Million | 1.317x | -71.60% |
| 2023-12-31 | $83.81 Million | $388.57 Million | 4.636x | +227.87% |
| 2022-12-31 | $169.80 Million | $240.11 Million | 1.414x | -6.99% |
| 2021-12-31 | $196.95 Million | $299.44 Million | 1.520x | +314.12% |
| 2020-12-31 | $151.05 Million | $55.45 Million | 0.367x | +139.44% |
| 2019-12-31 | $91.77 Million | $-85.42 Million | -0.931x | -368.05% |
| 2018-12-31 | $248.89 Million | $-49.50 Million | -0.199x | -130.91% |
| 2017-12-31 | $208.37 Million | $134.05 Million | 0.643x | -58.52% |
| 2016-12-31 | $-32.48 Million | $-50.38 Million | 1.551x | +279.86% |
| 2015-12-31 | $43.00 Million | $-37.08 Million | -0.862x | +24.95% |
| 2014-12-31 | $41.35 Million | $-47.52 Million | -1.149x | -146.56% |
| 2013-12-31 | $-19.99 Million | $-49.34 Million | 2.468x | +287.44% |
| 2012-12-31 | $48.85 Million | $-64.33 Million | -1.317x | +58.22% |
| 2011-12-31 | $10.90 Million | $-34.35 Million | -3.151x | -41.31% |
| 2010-12-31 | $20.35 Million | $-45.39 Million | -2.230x | +61.65% |
| 2009-12-31 | $6.90 Million | $-40.15 Million | -5.816x | -152.86% |
| 2008-12-31 | $15.38 Million | $-35.37 Million | -2.300x | -89880.87% |
| 2007-12-31 | $57.77 Million | $-147.66K | -0.003x | -100.83% |
| 2006-12-31 | $23.08 Million | $7.08 Million | 0.307x | +142.97% |
| 2005-12-31 | $18.21 Million | $-13.00 Million | -0.714x | -37.11% |
| 2004-12-31 | $14.82 Million | $-7.72 Million | -0.521x | +89.46% |
| 2003-12-31 | $10.06K | $-49.73K | -4.942x | -669.13% |
| 2002-12-31 | $86.81K | $-55.78K | -0.642x | +57.31% |
| 2001-12-31 | $22.84K | $-34.37K | -1.505x | -- |
About Halozyme Therapeutics Inc
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as smal… Read more